Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXI™ provides complete protocol support for AXI3™, AXI4™, AXI4-Lite™, AXI4-Stream™, ACE™, ACE-Lite™ , AHB™ and APB™ interfaces. ... Synopsys® VC ...
Ever since the COVID-19 pandemic began to ease, Moderna has weathered a sharp revenue downturn. But a new FDA approval shows that the company's scientific engine is no one trick pony. Moderna's ...
The Food and Drug Administration approved Moderna's vaccine for respiratory syncytial virus. The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...
Credit: Moderna. The approval was based on data from the phase 3 ConquerRSV trial, which included approximately 37,000 adults 60 years of age and older. The Food and Drug Administration (FDA) has ...
, opens new tab respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product. Moderna's vaccine was approved for ...
The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the name of ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Moderna has received its second drug approval from US regulators for an RSV vaccine in older adults, a step ...